


## PHARMACEUTICAL 2018



## INTEGRATED BIOPHARMA INC Rank 80 of 349





## PHARMACEUTICAL 2018



## INTEGRATED BIOPHARMA INC Rank 80 of 349

The relative strengths and weaknesses of INTEGRATED BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTEGRATED BIOPHARMA INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 967% points. The greatest weakness of INTEGRATED BIOPHARMA INC is the variable Other Expenses, reducing the Economic Capital Ratio by 701% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 294% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	12,551
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,155
Liabilities, Non-Current	4,246
Other Assets	1,044
Other Compr. Net Income	0
Other Expenses	39,797
Other Liabilities	5,724
Other Net Income	-1,331
Property and Equipment	1,601
Research and Development	0
Revenues	46,954
Selling, General and Administrative Expense	3,480

Output Variable	Value in 1000 USD
Assets	15,196
Liabilities	21,125
Expenses	43,277
Stockholders Equity	-5,929
Net Income	2,346
Comprehensive Net Income	2,346
Economic Capital Ratio	17%